title: Successful PBSC mobilization with high-dose G-CSF for patients failing a first round of mobilization.
abstract: PBSC are the preferred source of stem cells for autologous transplantation. However, regardless of the mobilization procedure used, 10%-20% of patients fail to collect an adequate number to ensure prompt engraftment. There is as yet no standard mobilization procedure for patients who fail a first mobilization attempt. Here, we describe a highly efficient strategy to obtain an adequate number of stem cells for patients who failed a first mobilization attempt. Seventy-four patients with various hematologic malignancies underwent initial mobilization with various regimens including hematopoietic growth factors with or without chemotherapy. In 72% of patients, > or =2 x 10(6) CD34+ stem cells/kg were collected in the initial mobilization attempt, and patients engrafted in a median of 10 days for neutrophils and 12 days for platelets. Eighteen patients failed to mobilize adequate numbers of stem cells, defined as the inability to collect 0.2 x 10(6) CD34+ stem cells/kg/day in the first 2-3 days. These patients had their apheresis halted. Patients were immediately given G-CSF (32 microg/kg/day) for 4 days as a second attempt at mobilization. Eighty-eight percent of these patients achieved the target of > or =2 x 10(6) CD34+ cells/kg, with a median duration of apheresis of 5 days (including the first and second mobilizations). The mean CD34+ cells/kg/day increased after administration of high-dose G-CSF from 0.16 after the first mobilization attempt to 0.61 (p = 0.0002) after the second mobilization. All patients engrafted in a median of 11 and 13 days for neutrophils and platelets, respectively. We conclude that patients whose apheresis yield is <0.4 x 10(6) CD34+ cells/kg after the first two apheresis collections can be successfully mobilized if high-dose G-CSF is administered immediately and continued until achieving > or =2 x 10(6) CD34+ stem cells/kg.
authors.affiliation: University of Texas, Health Science Center and Audie L. Murphy Memorial VA Hospital, San Antonio 78284, USA.
authors.forename: Y
authors.initials: Y
authors.lastname: Gazitt
authors.forename: C O
authors.initials: CO
authors.lastname: Freytes
authors.forename: N
authors.initials: N
authors.lastname: Callander
authors.forename: T W
authors.initials: TW
authors.lastname: Tsai
authors.forename: M
authors.initials: M
authors.lastname: Alsina
authors.forename: J
authors.initials: J
authors.lastname: Anderson
authors.forename: L
authors.initials: L
authors.lastname: Holle
authors.forename: J
authors.initials: J
authors.lastname: Cruz
authors.forename: P
authors.initials: P
authors.lastname: Devore
authors.forename: M
authors.initials: M
authors.lastname: McGrath
authors.forename: G
authors.initials: G
authors.lastname: West
authors.forename: R
authors.initials: R
authors.lastname: Alvarez
authors.forename: W
authors.initials: W
authors.lastname: Montgomery
mesh_terms: D000328:Adult; D000368:Aged; D001772:Blood Cell Count / Q000187:drug effects; D006084:Graft Rejection; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage*; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008875:Middle Aged; D009369:Neoplasms / Q000628:therapy*; D014182:Transplantation, Autologous
chemical_list: D016179:Granulocyte Colony-Stimulating Factor